Q1 2021 Earnings

Revenue

$89M+11.1% YoY

Gross Profit

$73M82.6% margin

Operating Income

$45M51.1% margin

Net Income

$40M44.9% margin

EPS (Diluted)

$0.25

QoQ Revenue Growth

-23.9%

Operating Cash Flow

$74M

Free Cash Flow

$74M

Stock-Based Comp.

$5M

Total Assets

$599M

Total Liabilities

$489M

Stockholders' Equity

$110M

Cash & Equivalents

$440M

Metric	Current	Year Ago	Change
Revenue	$89M	$80M	+11.1%
Gross Profit	$73M	$78M	-5.6%
Operating Income	$45M	$13M	+243.2%
Net Income	$40M	$3M	+1093.6%

Collaborative Arrangements

$89M99%

Collaborative Arrangement Collaboration And License Agreements

$200,0000%

Active Pharmaceutical Ingredient

$180,0000%

Royalty

$100,0000%

Collaborative Arrangement Transition Services Agreement

$100,0000%

Canada And Mexico

$600,00052%

North America

$550,00048%